Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in Southwestern Pennsylvania, 2005-2007

Preventing Chronic Disease

Volumn 7, Issue 5, 2010, Pages

  Smith, Kenneth J ^b   Hsu, Heather E ^b   Roberts, Mark S ^b   Kaye Kramer, M ^b   Orchard, Trevor J ^b   Piatt, Gretchen A ^b   Seidel, Miriam C ^b   Zgibor, Janice C ^b   Bryce, Cindy L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; COMMUNITY CARE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIET; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; SENSITIVITY AND SPECIFICITY; TIME; UNITED STATES;

CARDIOVASCULAR DISEASES; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIET; HUMANS; LIFE STYLE; MARKOV CHAINS; PENNSYLVANIA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 79952109656     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
2. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20(4):537-44.
3. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1390-2.
4. Ramachandran A, Snehealatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance. Diabetologia 2006;49:289-97.
5. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-34.
6. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study. Lancet 2008;371(9626):1783-9.
7. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368(9548):1673-9.
8. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically underserved community: a non-randomized prospective intervention study. Diabetes Care 2008;31(4):684-9.
9. Ackermann R, Finch E, Brizendine E, Zhou H, Marrero D. Translating the Diabetes Prevention Program into the community. The DEPLOY Study. Am J Prev Med 2008;35(4):357-63.
10. Absetz P, Valve R, Oldenburg B, Heinonen H, Nissinen A, Fogelholm M, et al. Type 2 diabetes prevention in the "real world": one-year results of the GOAL Implementation Trial. Diabetes Care 2007;30(10):2465-70.
11. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143(4):251-64.
12. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142(5):323-32.
13. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese US adults. Diabetes Care 2007;30(11):2874-9.
14. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25(12):2165-71.
15. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003;26(1):36-47.
16. Kramer MK, Miller R, Venditti E, Orchard TJ. Group lifestyle intervention for diabetes prevention in those with metabolic syndrome in primary care practice. Diabetes 2006;55(6 Suppl 1): A517.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
19. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142(8):611-9.
20. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006;113(25):2914-8.
21. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33(7):1776-81.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-47.
23. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
24. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81(9):1158-62.
25. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2): S54-64.
26. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25(12):2238-43.
27. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36(6):778-92.
28. Zhou H, Isaman DJ, Messinger S, Brown MB, Klein R, Brandle M, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28(12):2856-63.
29. Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality. http://www.meps.ahrq.gov/mepsweb. Accessed April 20, 2010.
30. Arias E. United States life tables, 2003. Natl Vital Stat Rep 2006;54(14):1-40.
31. Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46(4):349-56.